Ravi Patel, MD
Ophthalmology · Jacksonville, FLNPI 1134133358
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Sight Sciences, Inc. at 42.9% of the total. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $155.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$24K
- Glaukos Corporation$12K
- Johnson & Johnson Surgical Vision, Inc.$11K
- Omeros Corporation$3K
- Alcon$2K
- Rxsight Inc$504
- plus $3K from 23 others
What the payments were for
- Consulting fees$24,16644%
- Speaking & faculty fees$15,59728%
- Grants$2000%
- Travel & lodging$3,2046%
- Food & beverage$11,95222%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 95 | $23,672 |
| Glaukos Corporation | 28 | $12,375 |
| Johnson & Johnson Surgical Vision, Inc. | 53 | $10,957 |
| Omeros Corporation | 4 | $3,116 |
| Alcon | 62 | $1,610 |
| Rxsight Inc | 11 | $504 |
| Bausch & Lomb Americas Inc. | 18 | $488 |
| Amgen(2 entities) | 7 | $340 |
| AbbVie(2 entities) | 7 | $284 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $266 |
| Harrow Eye, LLC | 16 | $253 |
| Sun Pharmaceutical Industries Inc. | 6 | $227 |
| Oyster Point Pharma, Inc. | 4 | $213 |
| Carl Zeiss Meditec, Inc. | 4 | $168 |
| Astellas Pharma US Inc | 5 | $127 |
| Kala Pharmaceuticals, Inc. | 3 | $126 |
| Biotissue Holdings Inc. | 4 | $104 |
| Mallinckrodt Hospital Products Inc. | 4 | $77 |
| Carl Zeiss Meditec USA, Inc. | 2 | $34 |
| Dompe US, Inc. | 2 | $33 |
| Aerie Pharmaceuticals, Inc. | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Ivantis, Inc | 1 | $19 |
| Novartis | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Heron Therapeutics, Inc. | 2 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Emmaus Medical, Inc. | 1 | $16 |
| Lensar, Inc. | 3 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$14,385
- KXL System$10,975
- Tecnis Symfony IOL$7,583
- OMNI$7,012
- Tecnis Multifocal Family of 1-piece IOLS$4,902
- OMIDRIA$3,025
- Tecnis IOL$2,982
- Tecnis 1-piece IOL$1,451
- Tecnis 3-piece IOL$1,451
- Tecnis Symfony Toric IOL$1,451
- MEIBOMIAN GLAND EVALUATOR$1,200
- SION SURGICAL INSTRUMENT$500
- ReSTOR$252
- CE-marked KXLA system$248
- enVista MX60 IOL$229
- LUMIGAN$200
- RESTASIS MULTIDOSE$200
- TYRVAYA$143
- Photrexa$141
- RXSIGHT CONTACT LENS$140
How this compares
$55,135 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 545 | $40,074 |
| LumiganBimatoprost | 34 | $22,727 |
| Ketorolac Tromethamine | 581 | $14,096 |
| VyzultaLatanoprostene Bunod | 15 | $10,353 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $7,944 |
| Latanoprost | 456 | $5,489 |
| Ofloxacin | 525 | $5,082 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $4,502 |
| Travoprost | 14 | $3,953 |
| Cyclosporine | 11 | $3,430 |
| Difluprednate | 23 | $2,439 |
| Brinzolamide | 11 | $2,121 |
| Brimonidine Tartrate | 79 | $1,975 |
| Timolol Maleate | 96 | $1,958 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 43 | $1,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $284 | $30,67152 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $488 | $10,35315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.